New York, NY (PRWEB) May 07, 2014
As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a group of medical researchers is seeking physician participation in a national registry that tracks the use of atypical antipsychotic medications in pregnant women. According to a report published by Clinical Psychiatry News on April 18th, the renewed call for doctors to submit patient information to the registry reflects a need for clear, substantial data involving this patient population, as the use of atypicals in pregnancy is on the rise. The report points out that a study published last August in the Journal of Clinical Psychopharmacology found that the major malformation rate among children born to women who took drugs like Risperdal was two times higher than those whose mothers were not treated with atypical antipsychotics. However, research published in BMJ Open in April of that year found no significant difference between the two groups.*
“The number of Risperdal lawsuits filed on behalf of individuals who allegedly suffered gynecomastia and other serious side effects due to its use is growing. The data collected by this registry will help to provide important clarification regarding the risks associated with Risperdal and other atypical antipsychotics,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Court documents indicate that more than 350 product liability claims involving Risperdal have been filed in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas. Dozens of these cases allege a link between the use of Risperdal and gynecomastia, a condition marked by the excessive growth of male breast tissue. The lawsuits further allege that Johnson & Johnson and its Janssen Pharmaceuticals unit concealed the association between Risperdal and male breast growth, as well as other serious complications. Plaintiffs in Risperdal lawsuits also claim that the companies improperly marketed the drug for use in children, long before its pediatric indications were approved in 2006. (Risperdal Litigation, case number 100300296)
On November 4, 2013, the U.S. Department of Justice (DOJ) announced that Johnson & Johnson and Janssen had agreed to pay $2.2 billion to settle civil and criminal charges involving the marketing of Risperdal and other medications. Among other things, the government had accused the drug makers of improperly marketing Risperdal for use in elderly dementia patients and children. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to their use of Risperdal may be entitled to compensation from Johnson & Johnson and Janssen. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.
*clinicalpsychiatrynews.com/single-article/more-conclusive-link-needed-on-teratogenicity-and-atypicals-in-pregnancy/4d91f10eb4cf78322f908e2cfe59436e.html, Clinical Psychiatry News, April 18, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com